News

PREZCOBIX is a once-daily, fixed-dose antiretroviral combination tablet containing 800 mg of darunavir, marketed as PREZISTA in the United States, and 150 mg of cobicistat, a pharmacokinetic enhancer

This indication constitutes a population of patients with a serious and life-threatening condition reflected by a higher risk of progression to cirrhosis and liver failure. OCA is currently

The patent will expire no earlier than July 2032. The allowed claims cover a compound, pharmaceutical composition and method of treating certain cell proliferation diseases, including solid tumors,

Under the deal, Astellas is responsible to develop and commercialize Immunomic’s vaccine candidate JRC2-LAMP-vax, which is designed to treat allergies induced by Japanese red cedar pollen. Both the

Endo president and CEO Rajiv De Silva said: "This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality

In order to manage the regulatory submission to the Australian Therapeutics Goods Administration (TGA) and the up-and-coming clinical trial, ISCO has established an Australian subsidiary named Cyto Therapeutics.

Imbruvica is an once-daily oral therapy that inhibits a protein called Bruton’s tyrosine kinase (BTK). It also secured breakthrough therapy designation for WM from the FDA and is

Tarextumab is a fully human monoclonal antibody that targets the Notch2 and Notch3 receptors. Currently, the company is enrolling patients in a randomized Phase II trial of tarextumab

The once-daily Evotaz is a combination of the protease inhibitor atazanavir, marketed as Reyataz (atazanavir 200mg/300mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences. According to